drugset / Trial / NCT04613895
Treatment Effect According to Timing of Administration of DWP14012 40 mg
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to establish noninferiority of efficacy of DWP14012 (40 mg once daily) based on Timing of Administration.
Timeline
- Start
- 2020-11-17
- Primary completion
- 2021-05-30
- Completion
- 2021-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABEPRAZAN | Small molecule | 40 mg | Oral |